Paul A. Liberti, CEO and Chief Scientific Officer

A graduate of Columbia University’s Columbia College; Loyola University Chicago’s Stritch School of Medicine; Stevens Institute of Technology; post-doctoral work at: NJ College of Medicine/Thomas Jefferson Medical College (Immunochemistry); National Institute for Medical Research, Mill Hill, London (Cellular & Viral Immunology); Dr. Liberti was on the faculty of Thomas Jefferson Medical College for 16 years, rising from Assistant Professor to Full Professor in 5 years. A recipient of an NIH Career Development Award, he built a substantial National Institute of Health (NIH) funded research program and was Director of an Immunology Post-Doctoral Training Program funded by the National Institute for Allergy and Infectious Diseases (NIAID).  A principal speaker at several international symposia, he is globally recognized for his work on the structure of antibody combing sites and on studies regarding of the role (if any) of antibody conformational changes induced by reaction with germs as well as subsequent reactions with the complement system following antibody recognition.

Following a successful academic career at Thomas Jefferson Medical College (Professor of Immunology/Physical Biochemistry), he founded (1984) and managed Immunicon Corp. (NASDAQ: IMMC), a biotechnology firm based in Huntingdon Valley, PA for 16 years.  At Immunicon, he invented and developed: a broad spectrum of highly magnetic colloids for use in immunoassays and in cell diagnostics, novel high gradient quadrupole and hexapole separators as well as methods for immunoassays and cell selection. Dr. Liberti holds over 30 seminal U.S. patents in these areas.  In addition to leading the R&D program, he played a key role in Business Development particularly in corporate partnering (in excess of $30MM with 5 major firms) and VC funding (completing 3 rounds for $55MM) as well as the management and strategy of Immunicon’s IP patent portfolio.

Based on his insights and discoveries on the exquisite ability of these systems to find “the needle in the haystack” as regards cells in complex systems, he steered Immunicon into rare cell analysis (cancer cells) and developed, with a substantial research team that he recruited, a cancer diagnostic platform technology he named “CELLSEARCH®.”

Immunicon Corp. was acquired by Johnson & Johnson in 2008 who in 2003 created a new SBU around Immunicon’s CELLSEARCH® product suite and technology, J&J’s Veridex division (later Janssen Diagnostics & Janssen Oncology). In 2004, Immunicon was named Nanotechnology IPO of the Year by Small Times magazine.  Immunicon raised over a $100MM in private venture funding prior to its NASDAQ IPO in 2004 when it raised $155MM.

In 2009, the CELLSEARCH® Circulating Tumor Cell (CTC) Test was honored with the prestigious Prix Galien USA 2009 Award for Best Medical Technology. First awarded in the USA in 2009, the Prix Galien* recognizes the Best Medical, Biotechnology and Pharmaceutical Technology approved by the FDA in the past ten years.  With over 8 Nobel Laureates on the 2009 Prix Galien’s committee, the Prix Galien is the Nobel Prize of the commercial medical and biotechnology fields.

* The Prix Galien USA  committee judges which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule), is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee may decide on awards hors prix. The prizes are awarded for breakthrough, successful products and agents that improve the human condition.

Ted L. Liberti, COO & EVP of Business Development

Ted L. Liberti, COO & EVP for Business Development, oversees BioMag’s business development, finance and strategic partnering initiatives for: cell & gene therapy (CGT) clinical-scale cell selection systems (X-GRAFFETM), life science research market products (FEOSS), biopharma and bioprocessing. Fluent with ferrofluid manufacture & technology, he is well versed in BioMag’s technologies, product development, product markets, manufacturing, IP, quality systems & the rapidly evolving CGT ecosystem for CAR-T cell and gene therapy (GT).  He oversees BioMag’s intellectual property (IP) estate and patent filings that include over 7 PCT international patent applications for BioMag’s X-GRAFFETM & FEOSS cell selection systems.  He also oversees BioMag’s NIH SBIR applications to the NIH & the National Heart, Lung & Blood Institute (NHLBI) whose NIH SBIR funding has underwritten BioMag’s X-GRAFFETM Clinical-Scale Cell Selection product development.

Ted holds a B.S. in Economics from Penn State University and an M.A. in Applied Economics from the University of Delaware. Ted completed doctoral research in economics, strategy & entrepreneurship at Penn State’s Smeal College of Business and Department of Economics. He holds an M.B.A. in international corporate strategy from the University of Delaware with high honors. Fluent in French, Ted started his career in international banking with JP Morgan Paris to learn first-hand about financial markets, investment banking and the French economy. Later with Immunicon Corp. (NASDAQ: IMMC), he helped drive Immunicon’s business development, business strategy, contract research projects & collaborations with:  bioMérieux S.A., Guerbet S.A. and French academic groups in Paris & Lyon and advised on the valuation of Immunicon’s MRI contrast agent patents, leading to a $750,000 licensing arrangement with Sweden’s Nycomed Pharmaceuticals. From 2006 to 2012, he advised Ben Franklin Technology Partners’ (BFTP) portfolio of:  life science, medical device and IT early-stage companies on: business development, marketing, finance and strategy.

Dustin W. Ritter, Ph.D., Director of Research and Development

Dr. Ritter holds a B.S. in Biomedical Engineering from Louisiana Tech University. As an NSF Graduate Research Fellow, he conducted doctoral research aimed at developing an implantable optical glucose biosensor for people afflicted with diabetes. He has extensive experience with the encapsulation of proteins and nanomaterials within microcapsules constructed using the layer-by-layer technique to yield polyelectrolyte multilayer films. As a post-doctoral scholar at Penn State University, he was part of a small team developing low-cost microfluidic paper analytical devices, which hold great potential to be used for point-of-care screening and diagnostic purposes in low-resource settings.

Sai S. Patkar, M.S., Scientist 

Ms. Patkar graduated from the University of Mumbai with a B.E. in Biomedical Engineering in 2013. She holds an M.S. in Biomedical Engineering from Drexel University, where she was awarded the Dean’s Fellowship for superior scholarship during the course of the program. Her master’s research focused on developing polyelectrolyte multilayer films for localized antibiotic therapy by modifying implant surfaces.